ПЕРСПЕКТИВЫ ИСПОЛЬЗОВАНИЯ ПРОЛОНГИРОВАННЫХ ПРЕПАРАТОВ КОНЦЕНТРАТОВ ФАКТОРА СВЕРТЫВАНИЯ КРОВИ IX В ЛЕЧЕНИИ ГЕМОФИЛИИ В

Abstract

Hemophilia B is a hereditary disease of the blood clotting system caused by a deficiency or molecular abnormalities of blood clotting factor IX. The main method of treatment is intravenous administration of coagulation factor IX concentrates. To optimize treatment and increase patient adherence to therapy, concentrates with a prolonged half-life have been developed.